Persistence of multiply antibiotic-resistant campylobacter jejuni in a patient with the acquired immune deficiency syndrome

Dworkin, Brad M.; Wormser, Gary P.; Abdoo, Robert A.; Cabello, Felipe C.; Agüero, M E; Sivak, Steven L.

doi:10.1016/0002-9343(86)90646-7

Cited by 27 publications

(13 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The high prevalence of C. concisus at Rigshospitalet may be due to the hospital being a reference hospital serving severely ill and immunocompromised patients. The high incidence of persistent diarrhoea among immunocompromised patients has also been described for other Campylobacter species (26)(27)(28). Nevertheless, our use of the membrane lter method for routine isolation of Campylobacters and related bacteria is also of signi cance.…”

Section: Discussionmentioning

confidence: 92%

Prevalence of Campylobacter concisus in Diarrhoea of Immunocompromised Patients

Aabenhus

Permin²,

On³

et al. 2002

Scandinavian Journal of Infectious Diseases

View full text Add to dashboard Cite

The importance of Campylobacter species other than C. jejuni/coli in diarrhoeal disease is largely unknown. We wished to determine the prevalence and clinical presentation of C. concisus infection in patients with enteric disease in a tertiary hospital. Stool specimens were routinely tested for the presence of Campylobacter species, by use of the filter isolation method. The medical records of the C. concisus-positive patients were reviewed. Of 224 Campylobacter isolates obtained, 110 were identified as C. concisus. Concomitant infection occurred in only 27% of cases. By means of protein profiling we assigned C. concisus into 2 groups. The predominant C. concisus group 2 was the only strain to infect immunocompetent patients and children: 71% of the infected patients were immunocompromised, the majority being adults (84%). C. concisus may be a frequent cause of diarrhoea in immunocompromised patients. Two groups of C. concisus were found and these groups possibly vary in their pathogenic potential.

show abstract

Section: Discussionmentioning

confidence: 92%

Prevalence of Campylobacter concisus in Diarrhoea of Immunocompromised Patients

Aabenhus

Permin²,

On³

et al. 2002

Scandinavian Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…2). PCR primer sets were designed for four genes that have not been described together in the same strain of C. jejuni except in the genome of strain CG8421 (13). Both recrudescent strains were positive for these four genes (see Table S1 in the supplemental material).…”

Section: Resultsmentioning

confidence: 99%

“…In contrast to healthy hosts, prolonged clinical symptoms and the recrudescence of disease have been specifically reported in subjects with HIV infection and those with hypogammaglobulinemia (1,13,21,25,27,31,35). In these populations, campylobacteriosis may be associated with protracted shedding and gastrointestinal symptoms, as well as systemic disease.…”

Section: Discussionmentioning

confidence: 99%

“…Unlike individuals with immunodeficiencies, recrudescent infection with C. jejuni in healthy hosts who have received antibiotic therapy has not been previously reported (13,21,27). The recrudescence of infection with or without illness and in the absence of repeat exposure suggests that the original pathogen has not been completely eliminated from the host due to an insufficient immunologic response, containment of the microbe beyond the reach of antibiotics or host immunity, or the development of antibiotic resistance.…”

mentioning

confidence: 92%

See 1 more Smart Citation

Recrudescent Campylobacter jejuni Infection in an Immunocompetent Adult following Experimental Infection with a Well-Characterized Organism

Baqar

Tribble

Carmolli

et al. 2010

Clin Vaccine Immunol

View full text Add to dashboard Cite

The recrudescence of infection with Campylobacter jejuni after appropriate antibiotic treatment has not been previously reported in an immunocompetent adult. We present the complete clinical, microbiologic, and immunologic evaluation of a closely monitored healthy male with recrudescent C. jejuni infection occurring in the absence of immunodeficiency following experimental infection with a well-characterized strain. After antibiotic treatment, the initial infection was clinically cleared and microbiologically undetectable. Subsequently, two episodes of recrudescence occurred, with no change in in vitro antibiotic sensitivity being detected. The immune responses of the individual were compared to those of other participants in the experimental infection study: innate immune responses, including fecal cytokines and C-reactive protein, were intact; however, measures of Campylobacter-specific adaptive immune responses were absent, including serum antibodies, antibody-secreting cells, and in vitro gamma interferon responses. No primary or secondary immunodeficiency was identified. Recrudescent Campylobacter infections after treatment may be more common than has previously been appreciated. This work adds to our understanding of the human immune response to natural Campylobacter infection and reiterates the importance of pathogen-specific adaptive immune responses to this globally important pathogen.

show abstract

“…The disease may be atypical, with a severe, persistent, or relapsing pattern. [11][12][13] Acquired resistance to antibacterials usually effective in the treatment of campylobacteriosis has been reported. [12][13][14] This study reports the results of an investigation in which rifabutin prophylaxis of MAC infection in HIV-infected patients was evaluated in terms of its impact on the incidence of campylobacter diseases in these same patients.…”

Section: Discussionmentioning

confidence: 99%

Rifabutin Prophylaxis Against Mycobacterium Avium Complex Infections in HIV-Infected Patients: Impact on the Incidence of Campylobacteriosis

Pulik

Genet²,

Leturdu³

et al. 1999

AIDS Patient Care and STDs

View full text Add to dashboard Cite

Following the observation of the decreasing occurrence of campylobacteriosis in HIV-infected patients. This study examines the incidence of campylobacteriosis in patients who had received rifabutin prophylaxis against Mycobacterium avium complex (MAC) infection compared with the incidence observed among patients treated before the advent of rifabutin. A retrospective analysis (February 1992 to November 1995) was conducted in a hospital HIV inpatient unit. The study included two patient groups: 73 HIV-infected patients with CD4 counts of < 100 cells/microL (mean 30 cells/microL) who were treated between February 1992 and July 1993 and who had not received rifabutin prophylaxis (Group R-), as well as 90 HIV-infected patients with CD4 counts of < 100 cells/microL (mean 22 cells/microL) who had received rifabutin 300 mg/day as primary prophylaxis against MAC bacteremia between July 1993 and November 1995 (Group R+). For the patient population as a whole, 20 episodes of campylobacter infection were observed in 13 patients. Causative pathogens were Campylobacter jejuni (n = 10), C. coli (8), and unidentifiable (2). Seventeen episodes (in 12 patients) of campylobacter infection occurred in Group R- versus 3 episodes (in 2 patients) in Group R+ (p < 0.0005). The rate of symptomatic infection per 100 patient-months was 0.251 in Group R+ versus 2.02 in Group R-. The results of this study indicate that rifabutin prophylaxis was associated with a decrease in the rate of campylobacter infection in HIV-infected patients. These findings are supported by evidence that rifabutin is active against C. jejuni in vitro.

show abstract

Persistence of multiply antibiotic-resistant campylobacter jejuni in a patient with the acquired immune deficiency syndrome

Cited by 27 publications

References 36 publications

Prevalence of Campylobacter concisus in Diarrhoea of Immunocompromised Patients

Prevalence of Campylobacter concisus in Diarrhoea of Immunocompromised Patients

Recrudescent Campylobacter jejuni Infection in an Immunocompetent Adult following Experimental Infection with a Well-Characterized Organism

Rifabutin Prophylaxis Against Mycobacterium Avium Complex Infections in HIV-Infected Patients: Impact on the Incidence of Campylobacteriosis

Contact Info

Product

Resources

About